29th Jun 2026 12:02
29 June 2026
Genflow Biosciences Plc
Results of Annual General Meeting
Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.
Proxy Voting Results
Ordinary Resolutions | Votes for | % of votes cast for | Votes Against | % of votes cast against | Total votes cast | Votes withheld |
1. To receive and consider the Annual Report and Accounts for the year ended 31 December 2025 together with the Directors' Report and Auditors' Report thereon. | 102,370,028 | 99.94%
| 56,893
| 0.06%
| 102,426,921
| 1,058
|
2. To approve the directors' remuneration report for the financial period ended 31 December 2025 set out in the audited accounts for the financial period ended 31 December 2025. | 102,348,305
| 99.92%
| 78,616
| 0.08%
| 102,426,921
| 1,058
|
3. To re-appoint PKF Littlejohn LLP as auditors of the Company and to authorise the Directors of the Company to fix their remuneration. | 102,370,094
| 99.94%
| 56,603
| 0.06%
| 102,426,697 | 1,282
|
4. To re-elect Gad Berdugo as a Director of the Company.
| 102,363,749
| 99.93%
| 64,006
| 0.07%
| 102,427,755 | 224
|
5. To re-elect Dr Eric Leire as a Director of the Company.
| 102,363,557
| 99.93%
| 64,198
| 0.07%
| 102,427,755 | 224
|
6. To re-elect Tamara Joseph as a Director of the Company.
| 102,363,557
| 99.93%
| 64,198
| 0.07%
| 102,427,755 | 224
|
7. To re-elect Dr Yassine Bendiabdallah as a Director of the Company.
| 102,363,459
| 99.70%
| 64,296
| 0.30%
| 102,427,755 | 224
|
8. To re-elect Guy-Charles Fanneau De La Horie as a Director of the Company.
| 102,363,459
| 99.70%
| 64,296
| 0.30%
| 102,427,755 | 224 |
9. To approve the adoption of the share option scheme (the "Scheme") by the Company.
| 101,237,554
| 98.86%
| 1,162,031
| 1.13%
| 102,399,585 | 28,394 |
10. To authorise the Directors of the Company to allot shares for the Scheme Options (up to 14.34%)
| 101,264,434 | 98.86% | 1,162,321 | 1.14% | 102,426,465 | 1,224 |
11. To authorise the Directors of the Company to allot shares (up to 33%)
| 101,264,724 | 98.86% | 1,162,031 | 1.14% | 102,426,755 | 1,224 |
Special Resolution | Votes for | % of votes cast for | Votes Against | % of votes cast against | Total votes cast | Votes withheld |
12. To disapply statutory pre-emption rights in respect of Resolution 10 (Scheme Options)
| 101,218,852
| 98.82%
| 1,208,127
| 1.18%
| 102,426,979 | 1,000
|
13. To disapply statutory pre-emption rights in respect of Resolution 11 | 101,191,458 | 98.79% | 1,235,521 | 1.21% | 102,426,979 | 1,000 |
Contacts
Genflow Biosciences |
Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
About Genflow
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.
Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.
Related Shares:
Genflow Biosci